Shares of Bristol-Myers Squibb (NYSE:BMY) rose 1.5%

Bristol-Myers Squibb (NYSE:BMY – Get Free Report ) stock price rose 1.5% during trading on Friday. The stock traded as high as $42.48 and last traded at $42.14. 2,581,228 shares changed hands during trading, down 83% from the session’s average volume of 15,615,412 shares. Shares previously closed at $41.51.

Analyst upgrades and downgrades

Several research firms have recently commented on BMY. StockNews.com cut shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research note on Thursday. Societe Generale lowered shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Monday, March 11th. William Blair restated a “market perform” rating on shares of Bristol-Myers Squibb in a research note on Monday, April 1st. Wells Fargo & Company boosted their price objective on shares of Bristol-Myers Squibb from $51.00 to $52.00 and gave the company an “equal weight” rating in a research note on Thursday, April 18th . Finally, Barclays decreased their price objective on shares of Bristol-Myers Squibb from $51.00 to $43.00 and set an “equal weight” rating for the company in a research note on Friday. April 26. One analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and four have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $60.00, according to MarketBeat.

See the latest stock analysis on Bristol-Myers Squibb

Bristol-Myers Squibb trading rose 0.0%

The company’s fifty-day simple moving average is $42.97, and its 200-day simple moving average is $48.14. The company has a current ratio of 1.11, a quick ratio of 0.99, and a debt-to-equity ratio of 2.99. The stock has a market cap of $84.19 billion, a P/E ratio of -13.40, a price-to-earnings-growth ratio of 14.20 and a beta of 0.43.

Bristol-Myers Squibb (NYSE:BMY – Get Your Free Report ) last issued its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($4.40) EPS for the quarter, beating analysts’ consensus estimates of ($4.53) by $0.13. Bristol-Myers Squibb had a negative net margin of 13.50% and a positive return on equity of 8.83%. The firm had revenue of $11.87 billion for the quarter, compared to analyst estimates of $11.45 billion. In the same quarter last year, the firm earned $2.05 EPS. The company’s revenue increased by 4.7% year-on-year. As a group, analysts expect that Bristol-Myers Squibb will post 0.58 EPS for the current year.

Bristol-Myers Squibb announces dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, August 1st. Stockholders of record on Friday, July 5th will be given a dividend of $0.60 per share. This represents a dividend of $2.40 on an annualized basis and a yield of 5.78%. The ex-dividend date of this dividend is Friday, July 5. Bristol-Myers Squibb’s dividend payout ratio is currently -77.42%.

Institutional inputs and outputs

Hedge funds have recently modified their holdings of the business. McClarren Financial Advisors Inc. boosted its stake in Bristol-Myers Squibb by 532.7% in the fourth quarter. McClarren Financial Advisors Inc. now owns 1,879 shares of the biopharmaceutical company’s stock valued at $96,000 after purchasing an additional 1,582 shares in the last quarter. Institute for Wealth Management LLC. raised its stake in shares of Bristol-Myers Squibb by 1.0% in the fourth quarter. Institute for Wealth Management LLC. now owns 30,056 shares of the biopharmaceutical company’s stock valued at $1,542,000 after buying an additional 296 shares in the last quarter. Great Diamond Partners LLC boosted its stake in Bristol-Myers Squibb by 9.2% in the fourth quarter. Great Diamond Partners LLC now owns 4,372 shares of the biopharmaceutical company’s stock valued at $224,000 after purchasing an additional 367 shares in the last quarter. Global Assets Advisory LLC bought a new position in shares of Bristol-Myers Squibb in the first quarter valued at approximately $5,161,000. Finally, Principal Securities Inc. bought a new position in shares of Bristol-Myers Squibb in the 4th quarter valued at about $1,139,000. Institutional investors own 76.41% of the company’s shares.

Bristol-Myers Squibb Company Profile

(Get a free report)

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic and neuroscience. The company’s products include Eliquis for reducing the risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anticancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

Featured stories

Get news and reviews for Bristol-Myers Squibb Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Bristol-Myers Squibb and related companies with MarketBeat.com’s FREE daily email newsletter.